Fluticasone and Salmeterol Powder for Inhalation

October 25 [Fri], 2019, 19:35
Fluticasone and Salmeterol Powder for Inhalation



AirDuo Respiclick inhalation powder, Teva Respiratory, 232 mcg / 14 mcg, metered dose inhaler, 6 count, NDC 59310-0822-06
Fluticasone propionate / Salmeterol xinafoate inhalation powder, Teva Respiratory, 113 mcg / 14 mcg, metered dose inhaler, 1 count, NDC 00093-3608-82
Reason for the Shortage
Teva Respiratory did not provide a reason for the shortage.
Other fluticasone and salmeterol dry powder inhalers are not affected by the shortage.
Available Products
AirDuo Respiclick inhalation powder, Teva Respiratory, 113 mcg / 14 mcg, metered dose inhaler, 6 count, NDC 59310-0812-06
AirDuo Respiclick inhalation powder, Teva Respiratory, 55 mcg / 14 mcg, metered dose inhaler, 1 count, NDC 59310-0805-06
Fluticasone propionate / Salmeterol xinafoate inhalation powder, Teva Respiratory, 232 mcg / 14 mcg, metered dose inhaler, 1 count, NDC 00093-3609-82
Fluticasone propionate / Salmeterol xinafoate inhalation powder, Teva Respiratory, 55 mcg / 14 mcg, metered dose inhaler, 1 count, NDC 00093-3607-82
Estimated Resupply Dates
Teva Respiratory has AirDuo Respiclick fluticasone 232 mcg/salmeterol 14 mcg on back order and the company estimates a release date of mid-October 2019.
Teva Respiratory has fluticasone 113 mcg/salmeterol 14 mcg on back order and the company estimates a release date of mid-October 2019.pirbuterol
Updated
Updated October 8, 2019 by Rachael Freeman, PharmD, BCPS. Created March 7, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.
DISCLAIMER

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin.
コメントする
小文字 太字 斜体 下線 取り消し線 左寄せ 中央揃え 右寄せ テキストカラー 絵文字 プレビューON/OFF

不正な自動コメント投稿を防ぐため、チェックボックスにチェックをしてください。

利用規約に同意
 X 
禁止事項とご注意
※本名・メールアドレス・住所・電話番号など、個人が特定できる情報の入力は行わないでください。
「ヤプログ!利用規約 第9条 禁止事項」に該当するコメントは禁止します。
「ヤプログ!利用規約」に同意の上、コメントを送信してください。